Pgen stock forecast short interest in PGEN remains low

Short interest in PGEN remains low, enhancing the bullish case for the stock. PGEN stock forecast scenarios from quant models suggest that if revenue guidance improves, price could retest previous highs set earlier this year. Let's review some notable picks from our screened stocks. Management plans to seek accelerated approval for the drug in the RRP indication. Commercial preparations are currently underway for a potential 2026 launch of INO-3107, pending FDA approval. PGEN stock forecast indicates moderate volatility ahead, with Wall Street analysts projecting a potential upside if clinical trial milestones are met. Current market capitalization hovers near $240M, and technical charts show resistance around $1.90 while support stands near $1.